People
As COVID-19 has swept across the world, companies have had to make significant adjustments to the way business is conducted in a global economy. It has impacted all types of operations, including clinical trials.
Biopharma companies strengthen their leadership teams and boards with this week’s Movers & Shakers.
If you’re having trouble keeping up with multiple industry programs aimed at COVID-19, you’re not alone. But, there is a new solution that can help you see the proverbial forest from the trees – Signals Analytics COVID-19 Playbook.
Biopharma companies are attacking the COVID-19 pandemic from many fronts. Emergent BioSolutions is among those leading the fight.
The world continues to wait with bated breath for a treatment for COVID-19, and Pluristem Therapeutics appears to be on the cusp of providing some hope.
Although the data hasn’t been released yet, analysts are making predictions based on what little they do know.
The capital was raised from existing and new investors, including a broad range of institutional investors comprised of pharmaceutical companies, corporate pensions, financial institutions, endowments and foundations, family offices and funds-of-funds.
Following a setback with its experimental major depressive disorder drug in December, Sage Therapeutics will initiate a corporate restructuring that includes halving its employee headcount in order to focus its resources on the development of its pipeline.
The CDC findings were based on an analysis of 2,572 known juvenile cases of COVID-19 that were part of a batch of 149,760 laboratory-confirmed COVID-19 cases.
Disgraced pharma executive Martin Shkreli is pleading to be temporarily let out of prison in order to join in the fight against COVID-19, the disease that has swept across the globe infecting more than 1.3 million people across the globe.
PRESS RELEASES